Skip to content
Back to news

Servier strengthens its Research with two new partnerships

Share the article
Servier strengthens its Research with two new partnerships

Servier is starting 2026 by signing two major technology partnerships to support its research efforts: with Insilico Medicine and with Iktos. These collaborations, focused on artificial intelligence and robotics, aim to accelerate the discovery of new therapeutic solutions for patients.

Signed on January 4 and January 8 respectively, the two collaborations are designed to harness the full potential of artificial intelligence and robotics applied to drug discovery.

With Iktos, a French leader in artificial intelligence and robotics, Servier will rely on an integrated platform combining generative AI and automated chemistry to design, synthesize and optimize small molecules across multiple biological targets, particularly in oncology and neurology. This approach accelerates the iterative scientific process between molecular design, chemical synthesis and biological evaluation of drug candidates. Servier will then take the lead on the clinical development of the selected programs.

At the same time, the collaboration with Insilico Medicine, a China/US-based pioneer in AI-driven drug discovery, is built around the company’s proprietary Pharma.AI platform. The objective is to rapidly identify new drug candidates against complex oncology targets, using algorithms capable of exploring biological and chemical spaces that have so far remained difficult to access.
 

“The success of Servier’s oncology programs makes us a credible partner for mutually beneficial collaborations. These partnerships illustrate the complementarity between next-generation AI technologies and Servier’s scientific, translational and clinical expertise.”

Christophe Thurieau Executive Director of the Research Institute and Global Head of External Research at Servier

These two partnerships illustrate how Servier has become an attractive player for strategic collaborations, providing access to some of the most promising technological tools available today. They also reflect the growing international footprint of Servier’s collaborations: in China with Insilico Medicine, and in France and Europe with Iktos. This global approach enables Servier to benefit from the best available solutions while strengthening the Group’s international development.
 

Research & Innovation at Servier

Read more